Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Promising Hematologists Begin Year-Long Program To Pursue Careers In Clinical Research
Twenty hematology and hematology/oncology fellows and junior faculty will begin a unique year-long education and mentoring program this summer as part of the American Society of Hematology (ASH) Clinical Research Training Institute.
generic viagra online
Mate Selection: How Does She Know He'll Take Care Of The Kids?
Throughout the animal kingdom brilliant colors or elaborate behavioral displays serve as "advertisements" for attracting mates. But, what do the ads promise, and is there truth in advertising? Researchers at Yale theorize that when males must provide care for the survival of their offspring, the males" signals will consistently be honest - and they may devote more of their energy to caring for their offspring than to being attractive.
News of the day
New Data Support Use Of Simple Test To Predict Endometrial Cancer Response To Chemotherapy
New data presented at the 2009 American Society of Clinical Oncologist (ASCO) Annual Meeting support the use of a laboratory test, ChemoFX(R), to help physicians predetermine the effectiveness of chemotherapy in treating a woman"s endometrial cancer. Investigators found a significant correlation between the test results from 405 patient specimens analyzed using ChemoFx and published patient response rates for each chemotherapeutic regimen, suggesting less effective therapies could be eliminated prior to patient administration. Endometrial cancer is the most common gynecologic cancer among women in the United States.
Diagnostics

Gore Receives FDA Approval For Next Generation Of Large Diameter GORE VIABAHN(R) Endoprosthesis With Heparin Bioactive Surface

W. L. Gore & Associates (Gore) today announced that it has received approval from the US Food and Drug Administration (FDA) to market the most up-to-date design for the GORE VIABAHN® Endoprosthesis for device diameters 9 - 13 mm. The next generation of the large diameter product enables streamlined deployment on the same 0.035" guidewire and TIP to HUB direction as the 5 - 8 mm sizes. Additional modifications to the large diameter GORE VIABAHN Endoprosthesis include radial device expansion, a contoured proximal edge and a lower profile that is now available for most sizes. "The self-expanding, covered, GORE VIABAHN Endoprosthesis offers elegant and versatile endovascular solutions to difficult vascular problems," said Michael B. Silva, Jr., MD, Professor of Vascular Surgery, Professor of Radiology and Director of the Texas Vascular Center, University of Texas Medical Branch. "The latest improvements to the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface, including smaller delivery profile and 0.035" wire compatibility for the larger diameter endografts, will allow us to easily deliver the larger devices to more locations. Treating difficult vascular problems requires good skills and good equipment. We just got some cool new enhancements to our toys." The GORE VIABAHN Endoprosthesis family of devices is constructed with a durable, reinforced, biocompatible, expanded polytetrafluoroethylene (ePTFE) liner attached to an external nitinol stent structure. The product"s flexibility enables it to traverse tortuous areas and to conform to the complex anatomy of the artery. "The recent modifications to the GORE VIABAHN Endoprosthesis device underscores our commitment to continually provide our customers with next-generation, innovative products for the treatment of Peripheral Arterial Disease (PAD) in the iliac artery," said Erin Hutchinson with the Gore Peripheral Vascular Business. "Gore strives to be at the forefront of technology innovation and we"re pleased to provide interventionalists with an improved version of the large diameter devices that will allow more patients to receive safe and effective interventional therapies for the treatment of PAD in iliac arteries." The original device configuration in 6 - 8 mm sizes was initially approved by the FDA in 2005 for treating PAD in the superficial femoral artery (SFA). In 2007, Gore added a 5 mm size and made modifications to the device, including reducing its profile and adding a Heparin Bioactive Surface. In 2008, Gore received approval for large diameters of the GORE VIABAHN Endoprosthesis 9 - 13 mm for the indication of improving blood flow in patients with symptomatic peripheral artery disease in iliac artery lesions. Last month, Gore announced that the FDA approved a manufacturing change to the device in order to remove excess material at the device margin, resulting in a contoured edge at the proximal end. The device is the only stent-graft approved by the FDA for the treatment of patients suffering from PAD in superficial femoral and iliac artery lesions. W. L. Gore & Associates


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009